XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Intangible Assets, Net
 9 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net Goodwill and Intangible Assets, Net
In the second quarter of 2021, the Company implemented a new segment reporting structure which prompted changes in multiple reporting units across the Company. As a result, goodwill included in the impacted reporting units was reallocated using a relative fair value approach and assessed for impairment before and after the reallocation. The Company recorded a goodwill impairment charge of $69 million in the nine months ended December 31, 2020 as the estimated fair value of the Europe Retail Pharmacy reporting unit was lower than its reassigned carrying value based on changes in the composition of this reporting unit within the International segment. This impairment charge is included in “Goodwill impairment charges” in the Condensed Consolidated Statement of Operations.
The Company evaluates goodwill for impairment on an annual basis as of October 1, and at an interim date, if indicators of potential impairment exist. The annual impairment testing performed for 2022 and 2021 did not indicate any impairment of goodwill.
Changes in the carrying amount of goodwill were as follows:
(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical Solutions
International (1)
Total
Balance, March 31, 2021$3,963 $1,542 $2,453 $1,535 $9,493 
Goodwill acquired— — — 5 5 
Foreign currency translation adjustments, net(21)— — (15)(36)
Balance, December 31, 2021$3,942 $1,542 $2,453 $1,525 $9,462 
(1)    Remaining goodwill for this segment primarily relates to the McKesson Canada reporting unit.
Information regarding intangible assets is as follows:
 December 31, 2021March 31, 2021
(Dollars in millions)Weighted-
Average
Remaining
Amortization
Period
(Years)		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships12$2,842 $(1,718)$1,124 $3,739 $(2,269)$1,470 
Service agreements91,083 (558)525 1,081 (513)568 
Pharmacy licenses—— — — 497 (244)253 
Trademarks and trade names12816 (371)445 925 (394)531 
Technology2128 (113)15 150 (122)28 
Other8192 (171)21 254 (226)28 
Total $5,061 $(2,931)$2,130 
(1)
$6,646 $(3,768)$2,878 
(1)Excludes net intangible assets of approximately $452 million related to the European divestiture activities discussed in more detail in Financial Note 2, “Held for Sale.” This amount was included under the caption “Assets held for sale” in the Condensed Consolidated Balance Sheet as of December 31, 2021. Amortization of these assets ceased upon classification as Assets held for sale in the second and third quarters of 2022.
Amortization expense of intangible assets was $80 million and $262 million during the three and nine months ended December 31, 2021, respectively, and $108 million and $320 million during the three and nine months ended December 31, 2020, respectively. Estimated amortization expense of these assets is as follows: $70 million, $226 million, $215 million, $209 million, and $177 million for the remainder of 2022 and each of the succeeding years through 2026, respectively, and $1.2 billion thereafter. All intangible assets were subject to amortization as of December 31, 2021 and March 31, 2021.